ArticleOncotarget2016

Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.

Ilaria Penna et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.